IRCT20180205038626N7.

Study name	The investigation of the effectiveness of ASA usage on the incidence of cardiovascular events in patients with coronavirus (COVID‐19) A clinical trial study
Methods	Trial design: randomised single‐blinded trial, phase 2 Type of publication: trial registry Setting: Razi Hospital, Rasht Recruitment dates: 5 December 2020 Country: Iran Language: English Number of centres: NR Inclusion criteria: all patients admitted with a diagnosis of COVID‐19 based on CT scan or PCR; over 18 years Exclusion criteria: patients admitted to the ICU. Patients with a history of ulcers and gastrointestinal problems. Patients receiving aspirin. Patients with a history of thrombotic events such as heart attack or stroke or a history of atrial fibrillation, congestive heart failure, active bleeding or coagulation disorders such as thrombocytopenia. Trial registration number: IRCT20180205038626N7 Date of trial registration: 27 December 2020 Prospective completion date: not reported
Participants	Age: > 18 years Gender: NR Ethnicity: NR Number of participants (recruited/allocated/evaluated): 36/NR/NR Severity of disease: SARS‐CoV‐2 infection (COVID‐19) Additional diagnoses: NR Previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): NR
Interventions	Daily aspirin 80 mg for 3 months Standard treatment for 3 months Concomitant therapy: NR Treatment cross‐overs: NR Duration of follow‐up: NR Treatment cross‐overs: NR Compliance with assigned treatment: NR
Outcomes	Primary outcomes Thromboembolic events Cardiovascular accidents Brain accidents Secondary outcomes Death Additional outcomes: NR
Starting date	NR
Contact information	Contact: Zahra Ahmadnia, +98 13 3361 8177, zahmadnia@gums.ac.ir
Notes	Sponsor/funding: Rasht University of Medical Sciences COIs: NR Other: NR